Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion of medicines. This pause impacts a public health initiative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oqNlEpf
via IFTTT